



ASSOCIATION
FOR MOLECULAR
PATHOLOGY

ANNUAL

2018

REPORT





Contents

PAGE



President's Message	3
AMP Strategic Plan	4
Mission Statement	4
Vision Statement	5
Core Principles	5
2018 Board of Directors and Committee Chairs	6
Affiliations	7
Organizational Relationships	7
Advocacy and Clinical Practice	8
Membership and Annual Meeting Overview	9
International Education Initiatives	10
Financial Statement	11

Message

F R O M T H E P R E S I D E N T

Dear Colleagues,

Diagnostic molecular and genomic approaches are at the forefront of modern medicine. Since 1995, AMP's community of experts has advanced the clinical practice, science, and excellence of our field to provide the highest quality health care for patients.

Our society brings together an international, diverse and dynamic community: we are molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. Together, we develop clinical practice guidelines and share ground-breaking research in our academic publication, *The Journal of Molecular Diagnostics*. We advocate for patients at our places of work, as well as in the halls of government and regulatory agencies. We collaborate to create a comprehensive catalog of educational offerings, and we exchange key knowledge at our professional meetings.

AMP continues to grow and evolve every year. For the first time ever, our membership exceeds 2,500 individuals this year. Our international community grew by a remarkable 20% in 2018, and we now have members practicing in 51 countries.

In 2018, we hosted another exceptional Annual Meeting & Expo in San Antonio, Texas, where all aspects of new molecular testing were discussed. In addition, our Board of Directors decided to host an international meeting every year going forward, in order to engage members and medical professionals around the world. We hosted AMP Europe 2018 this spring in Rotterdam, The Netherlands, and we plan to return to the continent biennially in even years. The AMP Global meeting will move around the globe in odd years, and the next meeting will take place in Hong Kong in 2019.

Serving as your President has been a true honor. I look forward to our community's continued successes.

Sincerely,

Kojo S. J. Elenitoba-Johnson, MD
AMP President



AMP President Kojo S. J. Elenitoba-Johnson, MD (left) congratulates Jonathan Rothberg, PhD on his 2018 Award for Excellence in Molecular Diagnostics.

Strategic Plan

MISSION • VISION • PRINCIPLES




AMP'S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.

MISSION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** is a not-for-profit scientific society that advances the **CLINICAL PRACTICE, SCIENCE,** and **EXCELLENCE** of molecular and genomic laboratory medicine through **EDUCATION, INNOVATION,** and **ADVOCACY** to enable highest quality health care.





VISION STATEMENT


The **ASSOCIATION FOR MOLECULAR PATHOLOGY** seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:

- Activities that foster **INNOVATIVE** and **TRANSFORMATIVE PATIENT CARE** and the translation of scientific discoveries into diagnostic tests and services
- **EDUCATION PROGRAMS** that promote clinical laboratory testing of high quality and utility
- **ADVOCACY** that supports the practice of molecular pathology to enhance patient care, addresses regulatory and payment issues, and facilitates the adoption of innovative laboratory testing and technologies
- Activities that facilitate knowledge transfer and **COLLABORATION** among professionals worldwide

CORE PRINCIPLES

- Quality Health Care Through **EXCELLENCE** in Clinical Molecular Testing
- Fostering the **GLOBAL COMMUNITY** of Molecular Pathology Professionals
- **COLLABORATION** to Advance Molecular Pathology
- **ADVOCACY** that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- **INNOVATION** to Transform Patient Care





AMP

2018

BOARD OF DIRECTORS

PRESIDENT

Kojo S. J. Elenitoba-Johnson, MD
*University of Pennsylvania, Perelman
 School of Medicine*

PRESIDENT-ELECT AND STRATEGIC OPPORTUNITIES COMMITTEE CHAIR

Victoria M. Pratt, PhD
Indiana University Medical Center

PAST PRESIDENT AND NOMINATING COMMITTEE CHAIR

Federico A. Monzon, MD
Castle Biosciences

SECRETARY-TREASURER AND FINANCE COMMITTEE CHAIR

Daniel E. Sabath, MD, PhD
University of Washington Medical Center

CLINICAL PRACTICE COMMITTEE CHAIR

Antonia R. Sepulveda, MD, PhD
Columbia University Medical Center

ECONOMIC AFFAIRS COMMITTEE CHAIR

Samuel K. Caughron, MD
MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR

Ron M. Przygodzki, MD
Department of Veterans Affairs

PROFESSIONAL RELATIONS COMMITTEE CHAIR

Jordan Laser, MD
Northwell Health

PROGRAM COMMITTEE CHAIR

Lynne V. Abruzzo, MD, PhD
Ohio State University Medical Center

PUBLICATION & COMMUNICATION COMMITTEE CHAIR

Paul G. Rothberg, PhD
University Rochester Medical Center

TRAINING & EDUCATION COMMITTEE CHAIR

Cecilia Ching Sze Yeung, MD
Fred Hutchinson Cancer Research Center

GENETICS SUBDIVISION CHAIR

Birgit Funke, PhD
Veritas Genetics

HEMATOPATHOLOGY SUBDIVISION CHAIR

Annette Kim, MD, PhD
Brigham and Women's Hospital

INFECTIOUS DISEASES SUBDIVISION CHAIR

David R. Hillyard, MD
ARUP Laboratories, Inc.

INFORMATICS SUBDIVISION CHAIR

Alexis B. Carter, MD
Children's Healthcare of Atlanta

SOLID TUMORS SUBDIVISION CHAIR

Roger D. Klein, MD, JD
Klein & Klein Co. L.P.A.

INVITED GUEST INTERNATIONAL AFFAIRS COMMITTEE CHAIR

Rami Mahfouz, MD, MPH
*American University of Beirut
 Medical Center*

EXECUTIVE DIRECTOR

Mary Steele Williams,
 MNA, MT(ASCP)SM, CAE



Collaborations



INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences (2013)
 The Molecular Pathology Association of India (2013)
 The Korean Society for Laboratory Medicine (2013)
 The German Society of Pathology (2015)
 Brazilian Society of Clinical Pathology and Laboratory Medicine (2017)
 The Italian Society of Pathology and Translational Medicine (2017)
 American University of Beirut Medical Center (2018)

ORGANIZATIONAL RELATIONSHIPS

AMP maintains **MEMBERSHIP** in the following organizations:

The Pathology Roundtable
 Cancer Leadership Council (CLC)
 Federation of American Societies for Experimental Biology (FASEB)
 Global Alliance for Genomic Medicine
 Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
 Intersociety Pathology Council (IPC)
 Personalized Medicine Coalition (PMC)

AMP maintains **RELATIONSHIPS** with many organizations, including but not limited to:

Representative to ASCO CancerLinQ Steering Committee
 Cooperating Society of the American Board of Pathology (ABP)
 Steering Committee, NIST Genome in A Bottle Consortium
 Associate Member of the Intersociety Council for Pathology Information (ICPI)
 Sponsor of the National Academies Roundtable on Genomics and Precision Health
 Representatives to FNHI Biomarkers Consortium Steering Committees
 Representative to the College of American Pathology Pathology Coding Caucus (PCC)
 Representative to the CAP Molecular Oncology Committee





AMP ADVOCATES for excellence in molecular testing in clinical laboratories. We advance the field and practice of molecular pathology by representing the membership to the federal agencies and members of Congress to inform and influence public policy. AMP's clinical and scientific affairs initiatives aim to transform patient care through **INNOVATION**.

A D V O C A C Y

In 2018, AMP led and participated in numerous joint advocacy initiatives, hosted two "lunch and learns" with patient advocates, and held webinars on CPT® coding and changes to PAMA. In addition, AMP submitted over **35 ADVOCACY COMMENT LETTERS** on issues such as:

- National Coverage Determination for Next Generation Sequencing for Advanced Cancer Patients
- Draft Bills on Oversight of Laboratory Developed Testing Procedures
- Local Coverage Determinations for Molecular Pathology Procedures
- Protecting Access to Medicare Act (PAMA) Data Reporting and Implementation

I N N O V A T I O N & I M P R O V E D P A T I E N T C A R E

In 2018, over **200 MEMBER VOLUNTEERS** worked on AMP efforts to foster excellence in clinical practice and patient care. These efforts included AMP representation on outside collaborative projects or committees, and the publication of four major guideline projects:

Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines

J Mol Diagn. 2018 January; 20(1):4-27

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors


J Mol Diagn. 2018 March; 20(2):129-159

Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology

J Mol Diagn. 2018 May; 20(3):269-276


Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology

J Mol Diagn. 2018 November; 20(6):717-737



Engaging

MEMBERSHIP & MEETINGS



AMP ended the year with continued membership growth, rising from **2,417** in 2017 to **2,514** in 2018. Indicators suggest that growth will continue for the coming years. AMP members can be found in **51 COUNTRIES**.

Attendance continued to be strong at the **2018 ANNUAL MEETING**. We welcomed **2,100** attendees and approximately **190** companies. In addition, we welcomed over **300** attendees and **30** exhibiting companies at **AMP EUROPE**.

YEAR	LOCATION	SCIENTIFIC ATTENDEES
2011	GAYLORD TEXAN, TX	1,343
2012	LONG BEACH, CA	1,674
2013	PHOENIX, AZ	1,720
2014	WASHINGTON, DC	1,944
2015	AUSTIN, TX	2,084
2016	CHARLOTTE, NC	2,022
2017	SALT LAKE CITY, UT	2,201
2018	SAN ANTONIO, TX	2,106

AMP MEMBERS BY DEGREE:




Recipients of the Jeffrey A. Kant Leadership Award gathered at the 2018 Annual Meeting & Expo.

AMP Educating

A R O U N D T H E W O R L D & O N L I N E



AMP's educational initiatives continue to reach a global audience. In 2018, AMP hosted its first **AMP EUROPE** meeting in Rotterdam, **THE NETHERLANDS**. AMP invited speakers also presented at two AMP-affiliate society conferences in Bhubaneswar, **INDIA** and Seoul, **KOREA**. In addition, AMP hosted a luncheon for international attendees at the AMP 2018 Annual Meeting.




AMP received support to organize two webinar series in 2018: a 5-part series on Advancing Patient Care in NSCLC: Breaking Down Barriers and a 3-part series on Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care. These free programs (and their complimentary continuing education credit) are available through 2020.



The AMP learning management system, AMPED™, has more than 150 hours of cutting-edge molecular pathology content delivered by experts in the field. To learn more, visit educate.amp.org.






Financial

S T A T E M E N T

AMP's fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2018	2017	2016
Advocacy	\$ (490,772)	\$ (437,181)	\$ (426,435)
Communications & Outreach	\$ (125,071)	\$ (193,658)	\$ (174,649)
Education	\$ 2,021,273	\$ 1,932,749	\$ 2,299,693
Innovation & Improved Patient Care	\$ (250,296)	\$ (288,701)	\$ (290,237)
Membership & Management Services	\$ (220,128)	\$ (208,213)	\$ (32,781)
EXCESS REVENUE OVER EXPENSES	\$ 935,006	\$ 804,996	\$1,375,591





ASSOCIATION
FOR MOLECULAR
PATHOLOGY

6120 Executive Boulevard
Suite 700
Rockville, Maryland, 20852

CHAMP 



www.amp.org